Scientific output - Clinical and Experimental Respiratory Immunoallergy (IRCE) - Research

Research

Impact factor: duration: 2.85, total: 59.83

Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression

Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A, Friderich K, Jernigan K, Fu W, Ding Q, Pereda J, Serrano-Mollar A, Casanova A, Rodriguez-Becerra E, Morell F, Ancochea J, Picado C, Uhal BD
EUR RESPIR J. 2008; 32: 1004-1008. IF: 5.349
Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment

Serrano C, Guilarte M, Tella R, Dalmau G, Bartra J, Gaig P, Cerda M, Cardona V, Valero A
ALLERGY. 2008; 63: 735-741. IF: 5.014
Corticosteroid therapy increases membrane-tethered while decreases secreted mucin expression in nasal polyps

Martinez-Anton A, DeBolos C, Alobid I, Benitez P, Roca-Ferrer J, Picado C, Mullol J
ALLERGY. 2008; 63: 1368-1376. IF: 5.014
Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids

Pujols L, Alobid I, Bentiz P, Martinez-Anton A, Roca-Ferrer J, Fokkens WJ, Mullol J, Picado C
ALLERGY. 2008; 63: 1377-1386. IF: 5.014
Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases

Fraj J, Valero A, Vives R, Perez I, Borja J, Izquierdo I, Picado C
ALLERGY. 2008; 63: 112-115. IF: 5.014

Impact factor: duration: 2.95, total: 20.67

Allergic rhinitis management pocket reference 2008

Bousquet J, Reid J, VanWeel C, Cagnani CB, Canonica GW, Demoly P, Denburg J, Fokkens WJ, Grouse L, Mullol K, Ohta K, Schermer T, Valovirta E, Zhong N, Zuberbier T
ALLERGY. 2008; 63: 990-996. IF: 5.014
Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient's quality of life

Alobid I, Bernal-Sprekelsen M, Mullol J
ALLERGY. 2008; 63: 1267-1279. IF: 5.014

Inhibición del efecto de la administración nasal del Factor de Activación Plaquetaria (PAF) tras la administración de Rupatadina (NARUPAF)

Principal investigator : Valero AL. Funding source: Beca Grupo Uriach Pharma . Code: DC/03/RUP/I/08. Average: 09/01/2008 - 03/31/2010
Efecto de los inhibidores reversibles del proteasoma sobre la inflamación, la angiogénesis y la fibrosis en el asma.

Principal investigator : Pujols L. Funding source: Ministerio Sanidad y Consumo. Code: PI050057. Average: 01/01/2006 - 12/30/2008
Effects of reversible proteasome inhibitors on the mechanisms involved in inflammatory and remodelling responses in asthma

Principal investigator : Pujols L. Funding source: Fundació Marató TV3. Code: 40630. Average: 01/12/2005 - 01/11/2008
Global Allergy and Asthma European Network

Principal investigator : Mullol J. Funding source: Universiteit Gent Directie Financiën. Code: FOOD-CT-2004-506378. Average: 08/01/2008 - 01/31/2010
Bronquiestàsies i patologia nasosinusal

Principal investigator : Mullol J, Guilemany J. Funding source: Fundació Catalana de Pneumologia (FUCAP). Code: Ufesa07. Average: 07/01/2007 - 06/30/2009